Jennison Associates
STML

Jennison Associates’s Stemline Therapeutics, Inc. STML Stock Holding History

Jennison Associates’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-137,186
Closed -$2.69M – 797
2013
Q4 		$2.69M Buy
+137,186
New +$3.66M ﹤0.01% 548

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates's STML Position: Q1 2014 in Review

Jennison Associates sold out of Stemline Therapeutics, Inc. (STML) in Q1 2014, closing a stake of 137,186 shares — an estimated $2.69M sold.

Jennison Associates first reported a position in STML in Q4 2013 and held it in 1 quarter. The position peaked at $2.69M in Q4 2013. 61 funds tracked by Wall St. Rank hold STML as of Q1 2014.

  • Jennison Associates reported no remaining Stemline Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Jennison Associates sold 137,186 Stemline Therapeutics, Inc. shares in Q1 2014, an estimated $2.69M.
  • Jennison Associates first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 1 quarter.
  • Jennison Associates's Stemline Therapeutics, Inc. position peaked at $2.69M in Q4 2013.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2014.

Based on Jennison Associates's 13F filing for Q1 2014, filed 7 May 2014.